Mucopolysaccharidosis type 2
MONDO:0010674A lysosomal storage disease leading to a massive accumulation of glycosaminoglycans and a wide variety of symptoms including distinctive coarse facial features, short stature, cardio-respiratory involvement and skeletal abnormalities. It manifests as a continuum varying from a severe to an attenuated form without neuronal involvement.
Also known as: Hunter syndrome, Hunter's syndrome, I2S deficiency, IDS deficiency, MPS 2, MPS II, MPS with skin involvement, MPS2
27 clinical trials for this condition and its sub-types.
Follow this condition to get notified about new trialsSub-types
Broader categories
-
Early enzyme therapy may help kids with rare disease grow better
Disease control CompletedThis study followed 21 boys with Hunter syndrome who started taking Elaprase before age 6. Researchers tracked their height and weight for at least 5 years to see if the drug helps them grow more like other children. The study also monitored safety and compared growth data to unt…
Phase 4 • Sponsor: Shire • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Hunterase extended trial shows promise for managing hunter syndrome
Disease control CompletedThis study looked at the long-term safety and effectiveness of Hunterase (idursulfase beta) in 30 people with Hunter syndrome over about one year. Participants had either completed a previous phase 3 study or had used Hunterase for at least six months. The goal was to monitor sid…
Phase 3 • Sponsor: GC Biopharma Corp • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC